VEA
AKRO

Virtus ETF Advisers’s Akero Therapeutics AKRO Stock Holding History

Virtus ETF Advisers’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,449
Closed -$68.1K – 429
2024
Q4 		$68.1K Sell
2,449
-1,292
-35% -$39.1K 0.03% 394
2024
Q3 		$107K Buy
3,741
+64
+2% +$1.67K 0.05% 366
2024
Q2 		$86.3K Sell
3,677
-202
-5% -$4.32K 0.04% 379
2024
Q1 		$98K Sell
3,879
-269
-6% -$6.46K 0.05% 368
2023
Q4 		$96.9K Buy
4,148
+2,353
+131% +$46.4K 0.06% 371
2023
Q3 		$90.8K Sell
1,795
-176
-9% -$8.2K 0.06% 346
2023
Q2 		$92K Sell
1,971
-318
-14% -$14.6K 0.05% 413
2023
Q1 		$87.6K Sell
2,289
-875
-28% -$39K 0.05% 367
2022
Q4 		$173K Sell
3,164
-9,817
-76% -$421K 0.09% 323
2022
Q3 		$442K Buy
12,981
+99
+0.8% +$1.51K 0.18% 221
2022
Q2 		$122K Buy
12,882
+5,080
+65% +$53K 0.05% 378
2022
Q1 		$111K Sell
7,802
-464
-6% -$8.13K 0.05% 286
2021
Q4 		$175K Buy
8,266
+1,120
+16% +$24.8K 0.07% 263
2021
Q3 		$160K Sell
7,146
-380
-5% -$8.6K 0.07% 326
2021
Q2 		$187K Sell
7,526
-2,928
-28% -$82.3K 0.08% 375
2021
Q1 		$303K Buy
10,454
+178
+2% +$5.39K 0.13% 238
2020
Q4 		$265K Sell
10,276
-2,410
-19% -$67K 0.11% 288
2020
Q3 		$391K Sell
12,686
-1,739
-12% -$60.8K 0.21% 173
2020
Q2 		$359K Sell
14,425
-2,632
-15% -$60.1K 0.17% 254
2020
Q1 		$362K Sell
17,057
-2,474
-13% -$53.1K 0.15% 206
2019
Q4 		$433K Buy
+19,531
New +$404K 0.07% 230

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Virtus ETF Advisers's AKRO Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Akero Therapeutics (AKRO) in Q1 2025, closing a stake of 2,449 shares — an estimated $68.1K sold.

Virtus ETF Advisers first reported a position in AKRO in Q4 2019 and held it in 21 quarters. The position peaked at $442K in Q3 2022. 240 funds tracked by Wall St. Rank hold AKRO as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Akero Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 2,449 Akero Therapeutics shares in Q1 2025, an estimated $68.1K.
  • Virtus ETF Advisers first reported a position in Akero Therapeutics in Q4 2019 and held it in 21 quarters.
  • Virtus ETF Advisers's Akero Therapeutics position peaked at $442K in Q3 2022.
  • 240 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.